GSK Plc’s blood cancer drug failed to secure the backing of a panel of US regulatory advisers, putting its approval in doubt.

The British pharmaceutical company said combinations for its Blenrep drug were evaluated in adults with relapsed or ...

The U.S. FDA's panel of independent advisers on Thursday recommended against GSK's blood cancer drug Blenrep, citing concerns ...

FDA advisers on Thursday voted against GSK's blood cancer drug Blenrep, finding that its risks outweighed its benefits at the ...

On a quest to bring its multiple myeloma antibody-drug conjugate (ADC) Blenrep back to the U.S. | Members of the FDA's Oncologic Drugs Advisory Committee voiced concerns with ocular toxicity side ...

With GSK kicking its research and development engine into high gear in recent years, a shuffling of the scientific priorities ...

The U.S. Food and Drug Administration approved a pre-filled syringe version of GSK's blockbuster shingles vaccine Shingrix, ...

US FDA approves GSK’s Shingrix in a prefilled syringe presentation for prevention of shingles: London, UK Friday, July 18, 2025, 09:00 Hrs [IST] GSK plc announced that the US Fo ...

The U.S. Food and Drug Administration's staff reviewers on Tuesday raised safety concerns that GSK's blood cancer drug ...

The FDA has approved a prefilled syringe option of Shingrix which will streamline administration of GSK’s herpes zoster ...

GSK PLC closed 16.45% short of its 52-week high of £16.79, which the company reached on September 9th.

GSK remains confident in Blenrep’s safety and efficacy, and will work with the FDA as it reviews the drug, the company said ...